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LETTERS TO THE EDITOR
the work of the committee, which contained nephrolo-Relationship between
gists and methodologists who had no association with
the industry. To guarantee independence and objectivity,nonphenacetin combined
the committee members were chosen jointly by the in-
dustry and by the regulatory authorities of Germany,analgesics and nephropathy
Austria, and Switzerland. Representatives of both the
industry and regulatory groups attended the delibera-
tions, and the committee members received the custom-To the Editor: The paper by Feinstein et al in a recent
ary reimbursement for travel expenses and time.issue of Kidney International [1] is interesting reading but,
Two of Dr. Bennett’s other remarks require clarifica-in my opinion, it is unproductive to again rekindle the
tion. First, our committee did not “rekindle the debatedebate about the existence of analgesic nephropathy in
about the existence of analgesic nephropathy”; our focuslight of the impressive data of Elseviers et al [2, 3]. With-
was on evidence for a possible causal role for nonphenac-out discussing the substance of the debate, it would be
etin-containing analgesics. Second, for reasons stated inhelpful for the readers of Kidney International to know if
our review, we did not regard the opinions of Elseviersthere is any relationship between the German Medicines
et al as “impressive data.”Manufacturers Association and this study. The small
We hope Dr. Bennett shares our belief that scientificprint at the end of the article acknowledging support for
evidence is needed for progress in medical science.a 2-day meeting is insufficient to emphasize what is likely
a real or, certainly at best, a perceived conflict of interest.
Alvan R. Feinstein (Chairman)I would invite the authors to comment on the support
and Lothar A.J. Heinemann (Coordinator),
they were given for this article and any payment they on behalf of the Ad Hoc Review Committee
may have received as consultants for this effort. New Haven, Connecticut and Berlin, Germany
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Reply from the author “Chinese herbs nephropathy” is a very prejudicial term.
The introduction of our published review gave a de- The incorrect use of Aristolochia fangchi by Belgian prac-
tailed explanation of the historical background for our titioners [2] and nephritis induced by Cosyns et al [1]
Committee. Because German Drug Law requires the suggest that aristolochic acid is possibly associated with
industry to finance any investigations into the safety of nephropathy. Many hundreds of Chinese medicinal herbs
their drugs, the industry gave an unconditional grant for are safely used in China and throughout the world. The
Encyclopaedia of Traditional Chinese Medicinal Substances
documents 5767 entries, mostly botanical substances [3].
Many herbs and their combinations are used to treat 2001 by the International Society of Nephrology
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nephritis in Chinese hospitals. The term CHN may imply lochic acid-associated nephropathy (AAN) rather than
CHN in the furure.to readers that Chinese herbs in general cause renal
Han Y. Chen, Bo-Ying Ma, Alicia Grant,impairment. and Nick Lampert
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volving a specific nation needs to be carefully scrutinized.
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gen was designated as hepatitis B surface antigen. Indeed,
REFERENCES
any medical terms and statements tending to encourage
1. Cosyns JP, Dehoux JP, Guiot Y, et al: Chronic aristolochic acidprejudice and racism should be abandoned [4]. We feel toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney
strongly that the term CHN, which is etiologically mis- Int 59:2164–2173, 2001
2. Violon C: Belgian (Chinese herb) nephropathy: Why? J Pharm Belgleading and politically damaging, should follow suit. 52:7–27, 1997
We therefore hope that a reputable journal such as 3. Zhu Y-P, Woerdenbag HJ: Traditional Chinese herbal medicine.
Pharm World Sci 17:103–112, 1995Kidney International will play a leading role in adopting 4. van Ypersele de Strihou C: Chinese herbs nephropathy or the evils
nonprejudicial medical terms, specifically using aristo- of nature. Am J Kidney Dis 32:I-Iii, 1998
INSTRUCTIONS FOR LETTERS TO THE EDITOR
Letters to the Editor will be considered for publication, subject to editing. Letters referring to an article appearing in a recent issue of
Kidney International must be received within 2 months of publication of said article. Letters must contain information critical to a certain
area or must address recently published data. Letters must not exceed 250 words and contain no more than 4 references and 1 figure
or table. Financial associations or other possible conflicts of interest must be disclosed. If there is more than one author, a single
corresponding author should be named; this author is responsible for submitting corrections to page proofs.
Letters may be submitted by mail, fax, or E-mail. Letters sent by mail should be addressed to: Letters to the Editor, Kidney International,
Washington University School of Medicine at Barnes-Jewish Hospital (North Campus), Department of Medicine, Suite 4300, 216 South
Kingshighway Boulevard, St. Louis, MO 63110-1092, USA. Fax: 314-454-8907. E-mail: sklahr@imgate.wustl.edu
Receipt of letters will not be acknowledged, but authors of letters accepted for publication will be notified of its acceptance. Submission
of a letter to Kidney International constitutes permission for use of this letter by the journal’s copyright holder, the International Society
of Nephrology, or its licensees/assignees in any of Kidney International’s original, revised, or collected editions of any medium (print,
electronic, etc.) or form.
